Nonsteroidal Progesterone Receptor Modulators: Structure Activity Relationships

ABSTRACT

Progesterone, acting primarily via the progesterone receptor (PR), plays an essential role in the regulation of female reproduction. Steroidal progestins (i.e., PR agonists) are commonly used in women's health, such as in contraception and hormone therapy and for the treatment of gynecological disorders. Recent studies in women and in nonhuman primates also indicate that PR antagonists may have potential applications in contraception and for the treatment of reproductive disorders such as fibroids and endometriosis. Currently, all clinically available PR agonists and antagonists are steroidal compounds. They often cause various side effects due to their functional interactions with other steroid receptors or because of effects associated with their steroidal metabolites. In an effort to identify more receptor-selective and structurally diverse compounds that may render clinical advantages over steroidal PR ligands, numerous receptor-selective novel nonsteroidal PR agonists and antagonists have been discovered. This review focuses on the structure activity relationships and the biological profile of the nonsteroidal PR modulators discovered in the last decade.

KEYWORDS

Progesterone receptor (PR) - PR agonists - PR antagonists - contraception - endometriosis - hormone therapy - uterine fibroids

REFERENCES

• 1 Edgren R A, Sturtevant F M. Potencies of oral contraceptives.  Am J Obstet Gynecol. 1976;  125 1029-1038
• 2 Keating N L, Cleary P D, Rossi A S, Zaslavsky A M, Ayanian J Z. Use of hormone replacement therapy by postmenopausal women in the United States.  Ann Intern Med. 1999;  130 545-553
• 3 Utian W H, Shoupe D, Bachmann G, Pinkerton J V, Pickar J H. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate.  Fertil Steril. 2001;  75 1065-1079
• 4 Torgerson D J, Bell-Syer S EM. Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials.  JAMA. 2001;  285 2891-2897
• 5 Vercellini P, De Giorgi O, Oldani S et al.. Depot medroxyprogesterone acetate versus an oral contraceptive combined with very-low-dose danazol for long-term treatment of pelvic pain associated with endometriosis.  Am J Obstet Gynecol. 1996;  175 396-401
• 6 Glasier A, Baird D. The effects of self-administering emergency contraception.  N Engl J Med. 1998;  339 1-4
• 7 Brogden R N, Goa K L, Faulds D. Mifepristone: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential.  Drugs. 1993;  45 384-409
• 8 Slayden O D, Zelinski-Wooten M B, Chwalisz K, Stouffer R L, Brenner R M. Chronic treatment of cycling rhesus monkeys with low doses of the antiprogestin ZK 137 316: morphometric assessment of the uterus and oviduct.  Hum Reprod. 1998;  13 269-277
• 9 Zelinski-Wooten M B, Slayden O D, Chwalisz K et al.. Chronic treatment of female rhesus monkeys with low doses of the antiprogestin ZK 137 316: establishment of a regimen that permits normal menstrual cyclicity.  Hum Reprod. 1998;  13 259-267
• 10 Kettel L M, Murphy A A, Morales A J, Yen S S. Clinical efficacy of the antiprogesterone RU486 in the treatment of endometriosis and uterine fibroids.  Hum Reprod. 1994;  9(suppl 1) 116-120
• 11 Kettel L M, Murphy A A, Morales A J, Yen S S. Preliminary report on the treatment of endometriosis with low-dose mifepristone (RU 486).  Am J Obstet Gynecol. 1998;  178 1151-1156
• 12 Murphy A A, Kettel L M, Morales A J, Roberts V J, Yen S S. Regression of uterine leiomyomata in response to the antiprogesterone RU 486.  J Clin Endocrinol Metab. 1993;  76 513-517
• 13 Brenner R M, Slayden O D, Critchley H OD. Anti-proliferative effects of progesterone antagonists in the primate endometrium: a potential role for the androgen receptor.  Reproduction. 2002;  124 167-172
• 14 Zhang P, Terefenko E A, Fensome A et al.. Novel 6-aryl-1,4-dihydrobenzo[d]oxazine-2-thiones as potent, selective, and orally active nonsteroidal progesterone receptor agonists.  Bioorg Med Chem Lett. 2003;  13 1313-1316
• 15 Zhang Z, Lundeen S G, Zhu Y, Carver J M, Winneker R C. In vitro characterization of trimegestone: a new potent and selective progestin.  Steroids. 2000;  65 637-643
• 16 Pathirana C, Stein R B, Berger T S et al.. Nonsteroidal human progesterone receptor modulators from the marine alga Cymopolia barbata .  Mol Pharmacol. 1995;  47 630-635
• 17 Zhi L, Tegley C M, Kallel E A et al.. Aryl-1,2-dihydrochromeno[3,4-f]quinolines: a novel class of nonsteroidal human progesterone receptor agonists.  J Med Chem. 1998;  41 291-302
• 18 Palmer S, Campen C A, Allan G F et al.. Nonsteroidal progesterone receptor ligands with unprecedented receptor selectivity.  J Steroid Biochem Mol Biol. 2000;  75 33-42
• 19 Conti C J, Gimenez-Conti I B, Zerbe G O, Gerschenson L E. Differential effects of estradiol-17b and progesterone on the proliferation of glandular and luminal cells of rabbit uterine epithelium.  Biol Reprod. 1981;  24 643-648
• 20 McPhail M K. The assay of progestin.  J Physiol London. 1934;  83 145-156
• 21 Zhang Z, Funk C, Glasser S R, Mulholland J. Progesterone regulation of heparin-binding epidermal growth factor-like growth factor gene expression during sensitization and decidualization in the rat uterus: effects of the antiprogestin, ZK 98. 99.  Endocrinology. 1994;  135 1256-1263
• 22 Lundeen S G, Zhang Z, Zhu Y, Carver J M, Winneker R C. Rat uterine complement C3 expression as a model for progesterone receptor modulators: characterization of the new progestin trimegestone.  J Steroid Biochem Mol Biol. 2001;  78 137-143
• 23 Van Uem J FHM, Hsiu J G, Chillik C F et al.. Contraceptive potential of RU 486 by ovulation inhibition: I. Pituitary versus ovarian action with blockade of estrogen-induced endometrial proliferation.  Contraception. 1989;  40 171-184
• 24 Kloosterboer H J, Deckers G H, de Gooyer M E et al.. Pharmacological properties of a new selective antiprogestagen: Org 33628.  Ann N Y Acad Sci. 1995;  761 192-201
• 25 Kloosterboer H J, Deckers G H, Schoonen W GEJ et al.. Preclinical experience with two selective progesterone receptor modulators on breast and endometrium.  Steroids. 2000;  65 733-740
• 26 Zhang P, Fensome A, Wrobel J, Winneker R, Zhang Z. Non-steroidal progesterone receptor modulators.  Expert Opin Ther Pat. 2003;  13 1839-1847
• 27 Zhi L, Tegley C M, Pio B et al.. Nonsteroidal progesterone receptor antagonists based on 6-thiophenylhydroquinolines.  Bioorg Med Chem Lett. 2000;  10 415-418
• 28 Zhang P, Terefenko E A, Fensome A et al.. Potent nonsteroidal progesterone receptor agonists: synthesis and SAR study of 6-aryl benzoxazines.  Bioorg Med Chem Lett. 2002;  12 787-790
• 29 Beck C A, Weigel N L, Moyer M L, Nordeen S K, Edwards D P. The progesterone antagonist RU486 acquires agonist activity upon stimulation of cAMP signaling pathways.  Proc Natl Acad Sci USA. 1993;  90 4441-4445
• 30 Fensome A, Koko M, Wrobel J et al.. Novel 5-aryl-1,3-dihydro-indole-2-thiones: potent, orally active progesterone receptor agonists.  Bioorg Med Chem Lett. 2003;  13 1317-1320
• 31 Collins M A, Hudak V, Bender R et al.. Novel pyrrole-containing progesterone receptor modulators.  Bioorg Med Chem Lett. 2004;  14 2185-2189
• 32 Zhi L, Tegley C M, Pio B et al.. Benzylidene-1,2-dihydrochromeno[3,4-f]quinolines as selective progesterone receptor modulators.  J Med Chem. 2003;  46 4104-4112
• 33 Edwards J P, Zhi L, Pooley C LF et al.. Preparation, resolution, and biological evaluation of 5-aryl-1,2-dihydro-5H-chromeno[3,4-f]quinolines: potent, orally active, nonsteroidal progesterone receptor agonists.  J Med Chem. 1998;  41 2779-2785
• 34 Zhi L, Tegley C M, Edwards J P et al.. Alkyl-1,2-dihydrochromeno[3,4-f]quinolines: a novel class of nonsteroidal progesterone receptor modulators.  Bioorg Med Chem Lett. 1998;  8 3365-3370
• 35 Zhi L, Tegley C M, Pio B et al.. Synthesis and biological activity of 5-methylidene 1,2-dihydrochromeno[3,4-f]quinoline derivatives as progesterone receptor modulators.  Bioorg Med Chem Lett. 2003;  13 2071-2074
• 36 Tabata Y, Miike N, Hatsu M et al.. PF1092A, B and C, new nonsteroidal progesterone receptor ligands produced by Penicillium oblatum. I. Taxonomy of producing strain, fermentation, isolation and biological activities.  J Antibiot. 1997;  50 304-308
• 37 Tabata Y, Iizuka Y, Shinei R et al.. CP8668, a novel orally active nonsteroidal progesterone receptor modulator with tetrahydrobenzindolone skeleton.  Eur J Pharmacol. 2003;  461 73-78
• 38 Dong Y, Roberge J Y, Wang Z et al.. Characterization of a new class of selective nonsteroidal progesterone receptor agonists.  Steroids. 2004;  69 201-217
• 39 Pooley C LF, Edwards J P, Goldman M E et al.. Discovery and preliminary SAR studies of a novel, nonsteroidal progesterone receptor antagonist pharmacophore.  J Med Chem. 1998;  41 3461-3466
• 40 Zhi L, Ringgenberg J D, Edwards J P et al.. Development of progesterone receptor antagonists from 1,2-dihydrochromeno[3,4-f]quinoline agonist pharmacophore.  Bioorg Med Chem Lett. 2003;  13 2075-2078
• 41 Hamann L G, Winn D T, Pooley C LF et al.. Nonsteroidal progesterone receptor antagonists based on a conformationally-restricted subseries of 6-aryl-1,2-dihydro-2,2,4-trimethylquinolines.  Bioorg Med Chem Lett. 1998;  8 2731-2736
• 42 Zhang P, Terefenko E A, Wrobel J et al.. Synthesis and progesterone receptor antagonist activities of 6-aryl benzimidazolones and benzothiazolones.  Bioorg Med Chem Lett. 2001;  11 2747-2750
• 43 Fensome A, Bender R, Cohen J et al.. New progesterone receptor antagonists: 3,3-disubstituted-5-aryloxindoles.  Bioorg Med Chem Lett. 2002;  12 3487-3490
• 44 Zhang P, Terefenko E A, Fensome A et al.. Aryl-1,4-dihydro-benzo[d][1,3]oxazin-2-ones: a novel class of potent, selective, and orally active nonsteroidal progesterone receptor antagonists.  J Med Chem. 2002;  45 4379-4382
• 45 Winneker R C, Bitran D, Zhang Z. The preclinical biology of a new potent and selective progestin: trimegestone.  Steroids. 2003;  68 915-920
• 46 Bitran D, Shiekh M, McLeod M. Anxiolytic effect of progesterone is mediated by the neurosteroid allopregnanolone at brain GABAA receptors.  J Neuroendocrinol. 1995;  7 171-177